These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 1641370

  • 1. The relationship between cardiovascular complications of estrogen therapy and fibrinolysis in patients with prostatic cancer.
    Hasui Y, Marutsuka K, Nishi S, Kitada S, Osada Y, Sumiyoshi A.
    Prostate; 1992; 21(1):35-9. PubMed ID: 1641370
    [Abstract] [Full Text] [Related]

  • 2. Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products.
    van Hinsbergh VW, Bauer KA, Kooistra T, Kluft C, Dooijewaard G, Sherman ML, Nieuwenhuizen W.
    Blood; 1990 Dec 01; 76(11):2284-9. PubMed ID: 1701665
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Plasminogen activators and inhibitors in normal late pregnancy, postpartum and in the postnatal period.
    Koh CL, Viegas OA, Yuen R, Chua SE, Ng BL, Ratnam SS.
    Int J Gynaecol Obstet; 1992 May 01; 38(1):9-18. PubMed ID: 1348996
    [Abstract] [Full Text] [Related]

  • 5. Depression of tissue-type plasminogen activator and enhancement of urokinase-type plasminogen activator as an expression of local inflammation.
    Brommer EJ, Dooijewaard G, Dijkmans BA, Breedveld FC.
    Thromb Haemost; 1992 Aug 03; 68(2):180-4. PubMed ID: 1412164
    [Abstract] [Full Text] [Related]

  • 6. [Plasminogen activators (t-PA and u-PA) and other fibrinolysis parameters in patients with atherosclerosis obliterans and diabetic macroangiopathy].
    Zalewska-Rydzkowska D, Rość D, Ponikowska I, Michalski A, Graczykowska-Koczorowska A, Rydzkowski M.
    Pol Merkur Lekarski; 2001 Nov 03; 11(65):414-7. PubMed ID: 11852811
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The fibrinolytic system components are increased in systemic sclerosis and modulated by Alprostadil (alpha1 ciclodestryn).
    Bandinelli F, Bartoli F, Perfetto E, Del Rosso A, Moggi-Pignone A, Guiducci S, Cinelli M, Fatini C, Generini S, Gabrielli A, Giacomelli R, Maddali Bongi S, Abbate R, Del Rosso M, Matucci Cerinic M.
    Clin Exp Rheumatol; 2005 Nov 03; 23(5):671-7. PubMed ID: 16173244
    [Abstract] [Full Text] [Related]

  • 11. Lack of correlation between blood fibrinolysis and the immediate or post-operative blood loss in transurethral resection of the prostate.
    Nielsen JD, Gram J, Fabrin K, Holm-Nielsen A, Jespersen J.
    Br J Urol; 1997 Jul 03; 80(1):105-10. PubMed ID: 9240188
    [Abstract] [Full Text] [Related]

  • 12. Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor.
    Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Shen C, Newcomer LM, Goldhaber SZ, Hennekens CH.
    Circulation; 1992 May 03; 85(5):1822-7. PubMed ID: 1572039
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Tissue-type plasminogen activator and its inhibitor (PAI-1) in plasma in cases of non-insulin-dependent diabetes mellitus (NIDDM)].
    Jokaji H, Asakura H, Saito M, Uotani C, Kumabashiri I, Morishita E, Yamazaki M, Matsuda T.
    Nihon Ronen Igakkai Zasshi; 1990 Nov 03; 27(6):699-705. PubMed ID: 2127812
    [Abstract] [Full Text] [Related]

  • 16. [Tissue plasminogen activator (T-PA) and tissue plasminogen activator inhibitor (PAI-1) in patients after head injury].
    Beuth W, Kotschy M, Kasprzak HA, Rość D, Osiński P, Sniegocki M.
    Neurol Neurochir Pol; 1996 Nov 03; 30(3):427-34. PubMed ID: 8965977
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.